Rhythm Pharmaceuticals has asked the European Medicines Agency to fast-track its planned EU marketing authorization application (MAA) for setmelanotide, an investigational treatment for rare genetic disorders of obesity.
The EMA, which accepted setmelanotide on its priority medicines (PRIME) scheme for getting drugs for unmet medical needs to patients faster in 2018, was this week due to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?